• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.总体医疗费用与选择性5-羟色胺再摄取抑制剂使用模式(包括抗抑郁治疗时长)的关系——来自一个管理式医疗行政索赔数据库的结果
J Manag Care Pharm. 2005 Mar;11(2):145-50. doi: 10.18553/jmcp.2005.11.2.145.
2
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.文拉法辛与选择性5-羟色胺再摄取抑制剂(SSRI)抗抑郁治疗药物相互转换治疗重度抑郁症的药学及医疗成本。
J Manag Care Pharm. 2008 Jun;14(5):426-41. doi: 10.18553/jmcp.2008.14.5.426.
3
Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.在商业健康保险计划中,开始使用通用型与品牌型选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)抗抑郁药的成年患者的停药率和医疗保健成本。
J Manag Care Pharm. 2011 Mar;17(2):123-32. doi: 10.18553/jmcp.2011.17.2.123.
4
Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.使用第二代抗精神病药物或L-甲基叶酸作为辅助疗法对接受SSRI/SNRI治疗的抑郁症患者的依从性措施和资源利用进行比较评估。
J Manag Care Pharm. 2014 Jan;20(1):76-85. doi: 10.18553/jmcp.2014.20.1.76.
5
Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.与遵循美国国家质量保证委员会(NCQA)医疗效果数据和信息集(HEDIS)抗抑郁药物管理措施相关的更高成本和治疗因素:行政索赔分析
J Manag Care Pharm. 2006 Jan-Feb;12(1):43-54. doi: 10.18553/jmcp.2006.12.1.43.
6
Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.患有焦虑症的管理式医疗患者的抗抑郁药依从性与医疗资源使用情况
Psychiatr Serv. 2006 May;57(5):673-80. doi: 10.1176/ps.2006.57.5.673.
7
Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.使用选择性5-羟色胺再摄取抑制剂治疗经前烦躁障碍患者的管理式医疗费用比较。
J Clin Psychiatry. 2003 Dec;64(12):1511-6. doi: 10.4088/jcp.v64n1216.
8
A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.一项将西酞普兰与舍曲林作为抑郁症新发作的初始药物治疗进行比较的索赔分析:对抑郁症相关治疗费用的影响。
Clin Ther. 2004 Jan;26(1):115-24. doi: 10.1016/s0149-2918(04)90012-4.
9
Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.药物依从性和医疗资源利用模式的差异:老年与新型抗抑郁药在抑郁症和/或焦虑症患者中的应用
CNS Drugs. 2008;22(11):963-73. doi: 10.2165/00023210-200822110-00005.
10
Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.选择性5-羟色胺再摄取抑制剂(SSRI)仿制药阶梯式治疗药房福利设计的影响:焦虑症的经济模型
Am J Manag Care. 2005 Oct;11(12 Suppl):S370-9.

引用本文的文献

1
A systematic review and meta-analysis on impact of suboptimal use of antidepressants, bisphosphonates, and statins on healthcare resource utilisation and healthcare cost.一项关于抗抑郁药、双磷酸盐和他汀类药物使用不当对医疗资源利用和医疗成本影响的系统评价和荟萃分析。
PLoS One. 2022 Jun 29;17(6):e0269836. doi: 10.1371/journal.pone.0269836. eCollection 2022.
2
Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.与重度抑郁症患者不遵医嘱和不持续用药相关的医疗资源利用和费用。
J Manag Care Spec Pharm. 2021 Feb;27(2):223-239. doi: 10.18553/jmcp.2021.27.2.223.
3
Depression treatment and healthcare expenditures among elderly Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer.老年医疗保险受益人中患有新发抑郁症且患有乳腺癌、结直肠癌或前列腺癌的患者的抑郁症治疗和医疗保健支出。
Psychooncology. 2017 Dec;26(12):2215-2223. doi: 10.1002/pon.4325. Epub 2017 Jan 24.
4
Adherence and health care costs.依从性与医疗保健成本。
Risk Manag Healthc Policy. 2014 Feb 20;7:35-44. doi: 10.2147/RMHP.S19801. eCollection 2014.
5
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.精神分裂症或双相情感障碍患者出院时接受阿立哌唑、喹硫平或齐拉西酮治疗的药物依从性和利用情况:一项回顾性队列研究。
BMC Psychiatry. 2012 Aug 2;12:99. doi: 10.1186/1471-244X-12-99.
6
How patient cost-sharing trends affect adherence and outcomes: a literature review.患者费用分担趋势如何影响依从性和治疗结果:一项文献综述。
P T. 2012 Jan;37(1):45-55.
7
Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder.重度抑郁症管理式医疗患者中使用品牌抗抑郁药和通用型选择性5-羟色胺再摄取抑制剂(SSRI)的依从性和持续性。
Clinicoecon Outcomes Res. 2011;3:63-72. doi: 10.2147/CEOR.S17846. Epub 2011 Mar 15.
8
Should we treat depression with drugs or psychological interventions? A reply to Ioannidis.我们应该用药物还是心理干预来治疗抑郁症?对伊奥尼亚迪斯的回应。
Philos Ethics Humanit Med. 2011 May 10;6:8. doi: 10.1186/1747-5341-6-8.
9
Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.阿戈美拉汀治疗重性抑郁障碍:具有临床疗效的潜力。
CNS Drugs. 2010 Jun;24(6):479-99. doi: 10.2165/11534420-000000000-00000.

总体医疗费用与选择性5-羟色胺再摄取抑制剂使用模式(包括抗抑郁治疗时长)的关系——来自一个管理式医疗行政索赔数据库的结果

Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.

作者信息

Eaddy Michael T, Druss Benjamin G, Sarnes Matthew W, Regan Timothy S, Frankum Laura E

机构信息

Applied Health Outcomes, 3488 East Lake Rd., Suite 201, Palm Harbor, FL 34685, USA.

出版信息

J Manag Care Pharm. 2005 Mar;11(2):145-50. doi: 10.18553/jmcp.2005.11.2.145.

DOI:10.18553/jmcp.2005.11.2.145
PMID:15766321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10438321/
Abstract

OBJECTIVE

Administrative claims data analysis performed in the early 1990s found lower total medical costs for patients with depression who remained on antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) for at least 90 days compared with patients who discontinued therapy prior to 60 days. Over the past decade, many changes in the health care system have occurred that might impact the reproducibility of these findings. The purpose of this study was to investigate the association between SSRI utilization patterns and the use of health care services in the managed care environment.

METHODS

A large managed care claims database was used to identify patients receiving 2 or more SSRI prescriptions between June 2001 and December 2002. In order to ensure that patients were newly started on SSRI therapy, patients were required to have 6 months of enrollment data prior to their index date, without evidence of antidepressant therapy. Continuous enrollment for 12 months following their index prescription was also required. Patients with schizophrenia, bipolar disorder, or who received antipsychotic medications were excluded from this analysis. Patients were placed into 1 of 5 mutually exclusive antidepressant utilization cohorts: (1) <90 days, (2) e 90 days, (3) titration, (4) partial compliance, and (5) therapy change. Total medical costs, with and without pharmacy costs, were then compared between antidepressant utilization cohorts for 12 months of claims data.

RESULTS

There were 65,753 patients included in the study. Medical charges without pharmacy charges were lowest in the e 90-day cohort ($5,143) compared with the partial compliance ($5,909, P<0.05), <90-day ($6,289, P<0.001), titration ($6,375, P<0.001), and therapy change ($7,858, P<0.001) cohorts. Differences in total medical charges without pharmacy charges were primarily influenced by inpatient charges. The addition of pharmacy charges, including the charges for antidepressants, resulted in total medical charges that were not statistically different for the e 90-day cohort compared with the <90-day cohort, $7,454 and $7,829, respectively, P=0.606.

CONCLUSION

Medical charges without pharmacy charges were lower for patients remaining on antidepressant drug therapy for at least 90 continuous days compared with patients who used antidepressants for less than 90 continuous days, but total health care charges, including pharmacy charges, were not different between the 2 groups.

摘要

目的

20世纪90年代初进行的行政索赔数据分析发现,与在60天前停药的抑郁症患者相比,持续使用选择性5-羟色胺再摄取抑制剂(SSRI)进行抗抑郁治疗至少90天的患者的总医疗费用更低。在过去十年中,医疗保健系统发生了许多变化,这可能会影响这些研究结果的可重复性。本研究的目的是调查在管理式医疗环境中SSRI使用模式与医疗服务使用之间的关联。

方法

使用一个大型管理式医疗索赔数据库来识别在2001年6月至2002年12月期间接受2种或更多SSRI处方的患者。为确保患者是新开始接受SSRI治疗,要求患者在其索引日期前有6个月的参保数据,且无抗抑郁治疗证据。还要求在其索引处方后连续参保12个月。患有精神分裂症、双相情感障碍或接受抗精神病药物治疗的患者被排除在本分析之外。患者被分为5个相互排斥的抗抑郁药使用队列之一:(1)<90天,(2)≥90天,(3)滴定,(4)部分依从,和(5)治疗改变。然后比较抗抑郁药使用队列之间12个月索赔数据的总医疗费用(包括和不包括药房费用)。

结果

该研究纳入了65753名患者。不包括药房费用的医疗费用在≥90天队列中最低(5143美元),与部分依从队列(5909美元,P<0.05)、<90天队列(6289美元,P<0.001)、滴定队列(6375美元,P<0.001)和治疗改变队列(7858美元,P<0.001)相比。不包括药房费用的总医疗费用差异主要受住院费用影响。加上药房费用,包括抗抑郁药费用,≥90天队列的总医疗费用与<90天队列相比无统计学差异,分别为7454美元和7829美元,P=0.606。

结论

与连续使用抗抑郁药物少于90天的患者相比,连续使用抗抑郁药物治疗至少90天的患者不包括药房费用的医疗费用较低,但两组的总医疗费用(包括药房费用)无差异。